IDEAYA exercises option for license on Biocytogen’s IDE034

11 November 2024

US company IDEAYA Biosciences (Nasdaq: IDYA) has exercised the option for an exclusive worldwide license for Biocytogen Pharmaceuticals’ (HKEX: 02315) B7H3/PTK7 BsADC program, IDE034, and has nominated it as a development candidate.

IDEAYA is a San Francisco-based precision oncology firm, while Biocytogen is a Chinese biotech focused on the discovery of novel antibody/ADC therapeutics.

Yuelei Shen, president and chief executive of Biocytogen, said: “We are excited that IDEAYA has chosen to exercise their option to license the worldwide rights to our B7H3/PTK7 BsADC IDE034, which incorporates our proprietary topoisomerase linker-payload.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK